Page Title
Clinical Trial Finder
Observational Enrolling
SEND-CF: Study to identify new ways to diagnose harmful bacteria in the lungs of people with CF ages 16 and older (SENDCF-OB-25)
The SEND-CF study will gather health information and samples from people with CF to find new and better ways to spot harmful bacteria in the lungs.
This is an observational study so there is no drug involved. Participants will be asked to provide samples including sputum, saliva, blood, and urine at the study visit. Participants must be able to produce sputum to participate.
The study may require blood draws, sputum, saliva, and urine collection and/or other measures.
Email a research coordinator to express interest in participating in this study.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
16 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
30% or greater
For a more comprehensive list of eligibility criteria and details on this study, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Participants will need to have had at least 6 bacterial cultures within the previous 36 months (type of specimen: sputum, or induced sputum, or throat/nasal, or bronchoscopy).
Study Design
-
Study Type: ?more info
Observational -
Randomized Study: ?more info
No -
Placebo Controlled: ?more info
No -
Length of Participation:
1 days -
Number of Study Visits:
1
Additional Information
-
Phase: ?more info
Not Applicable -
Study Sponsor: ?more info
Hong, Gina -
Study Drugs:
N/A
Study Sites
-
Enrolling Soon
California
University of California San Diego, La Jolla, CA 92037
Contact
Phone: +1
Email:
-
Enrolling Soon
Colorado
National Jewish Health, Denver, CO 80206
Contact
Alix Wilson
Phone: +1 (303) 270-2517
Email: wilsona@njhealth.org
-
Enrolling
Minnesota
The Minnesota Cystic Fibrosis Center, Minneapolis, MN 55455
Contact
Participant Contact University of Minnesota
Phone: +1
Email: cftrials@umn.edu
-
Enrolling
Missouri
Washington University School of Medicine, St. Louis, MO 63110
Contact
Irma Bauer
Phone: +1 (314) 747-2940
Email: irmabauer@wustl.edu
-
Enrolling Soon
Nebraska
University of Nebraska Medical Center, Omaha, NE 68198
Contact
Michel Veit
Phone: +1 (402) 559-7585
Email: michel.veit@unmc.edu
-
Enrolling Soon
Ohio
Nationwide Children's Hospital, Columbus, OH 43205
Contact
Diana Gilmore
Phone: +1 (614) 722-4752
Email: diana.gilmore@nationwidechildrens.org
-
Enrolling
Pennsylvania
University of Pennsylvania, Philadelphia, PA 19104
Contact
Melissa Molter
Phone: +1 (215) 662-3116
Email: melissa.molter@pennmedicine.upenn.edu
-
Enrolling Soon
Pennsylvania
University of Pittsburgh Medical Center, Pittsburgh, PA 15224
Contact
Adrienne DeRicco
Phone: +1 (412) 692-8069
Email: adrienne.dericco2@upmc.edu
-
Enrolling
Texas
University of Texas Southwestern, Dallas, TX 75390
Contact
Ashley Keller
Phone: +1 (214) 648-6233
Email: Ashley.Keller@UTSouthwestern.edu
-
Enrolling Soon
Wisconsin
Froedtert & Medical College of Wisconsin, Milwaukee, WI 53226
Contact
Erin Hubertz
Phone: +1 (414) 955-7019
Email: ehubertz@mcw.edu
Email a research coordinator to express interest in participating in this study.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
16 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
30% or greater
For a more comprehensive list of eligibility criteria and details on this study, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Participants will need to have had at least 6 bacterial cultures within the previous 36 months (type of specimen: sputum, or induced sputum, or throat/nasal, or bronchoscopy).
CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More